<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-68120</identifier>
<setSpec>0001-6640</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Burkitt&#146;s lymphoma accounts for nearly 40% of the non-Hodgkin&#146;s lymphomas in childhood. There are three recognized clinical variants of Burkitt&#146;s lymphoma: Burkitt&#146;s lymphoma associated with immunodeficiency, sporadic Burkitt&#146;s lymphoma and endemic Burkitt&#146;s lymphoma, from Equatorial Africa. This is the paediatric tumour most frequent in Equatorial Africa, in the etiopathogeny of which the infection caused by the Epstein Barr virus and malaria act as co-factors. It shows clinical and molecular differences compared to the sporadic cases, such as: the characteristic involvement of the bones of the face, mainly the jaw followed by the eye socket; the greater frequency of the involvement of the central nervous system, of the salivary glands and of the thyroid glands; and the lesser frequency of the infiltration of the bone marrow. The treatment is based on combined chemotherapy, with the prevention of the tumour lysis syndrome being crucial in the initial treatment. The results of the sporadic and endemic Burkitt&#146;s lymphoma are superimposable with regard to the rates of response, relapse and survival rates(AU)</dc:description>
<dc:creator>Mata Fernández, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El linfoma de Burkitt supone casi un 40% de los linfomas no hodgkinianos en la infancia. Se reconocen tres variantes clínicas: asociado a inmunodeficiencia, esporádico y endémico, propio del África ecuatorial. Éste es el tumor pediátrico más frecuente en África ecuatorial, en cuya etiopatogenia actúan como cofactores la infección por el virus de Epstein-Barr y la malaria. Presenta diferencias clínicas y moleculares con los casos esporádicos, como la característica afectación de los huesos de la cara (principalmente de la mandíbula, seguida de la órbita), la mayor frecuencia de afectación del sistema nervioso central, de las glándulas salivales y del tiroides, y la menor frecuencia de infiltración de la médula ósea. El tratamiento se basa en quimioterapia combinada, y en el tratamiento inicial es crucial la prevención del síndrome de lisis tumoral. Los resultados del linfoma de Burkitt esporádico y endémico son superponibles, respecto a las tasas de respuesta, recaídas y supervivencia(AU)</dc:description>
<dc:source>Acta Pediatr Esp;66(7): 322-326, jul. 2008. ilus</dc:source>
<dc:identifier>ibc-68120</dc:identifier>
<dc:subject>^d24339^s22045</dc:subject>
<dc:subject>^d24511^s22073</dc:subject>
<dc:subject>^d33755^s22080</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33755^s22012</dc:subject>
<dc:subject>^d28213^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d19237^s22080</dc:subject>
<dc:subject>^d29351^s22080</dc:subject>
<dc:subject>^d14563</dc:subject>
<dc:subject>^d19237^s22012</dc:subject>
<dc:subject>^d19184^s22012</dc:subject>
<dc:subject>^d86^s22073</dc:subject>
<dc:subject>^d19184^s22080</dc:subject>
<dc:subject>^d19237^s22016</dc:subject>
<dc:subject>^d7574^s22012</dc:subject>
<dc:subject>^d29351^s22016</dc:subject>
<dc:subject>^d8506^s22053</dc:subject>
<dc:subject>^d8506^s29166</dc:subject>
<dc:subject>^d15155^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200807</dc:date>
</metadata>
</record>
</ibecs-document>
